ELZA at ESCRS 2024 – Day 3
Sunday, September 8th is the third day of the ESCRS 2024 meeting of the European Society of Cataract and Refractive Surgeons.
Mark Hillen
September 8, 2024
Sunday, September 8th is the third day of the ESCRS 2024 meeting of the European Society of Cataract and Refractive Surgeons.
Saturday, September 7 is the second day of the ESCRS 2024 meeting of the European Society of Cataract and Refractive Surgeons.
Friday, September 6 was the first day of the ESCRS 2024 meeting of the European Society of Cataract and Refractive Surgeons. Here’s a collection of images from that day.
The STEP system utilizes two parameters: the minimum overall stromal thickness (ST) and the standard deviation of epithelial thickness (EP). This approach provides a more detailed understanding of keratoconus progression, offering insights that may assist in clinical decisions, especially concerning corneal cross-linking (CXL) protocols.
ELZA-PACE not only improves corneal biomechanics (just like regular CXL) but by flattening the cone significantly, also enhances patients’ visual quality. The results so far indicate that patients treated with this method have better visual outcomes compared to traditional CXL treatments.
Here’s an overview of what ELZA’s surgeons and researchers are presenting in Barcelona this year. ELZA at ESCRS 2024.
On August 12, 2023, at Humo Arena, Tashkent, 63 Down syndrome children were screened for keratoconus under Nikki Hafezi’s leadership. Discover the importance of early detection.
Ophthalmologie Nachrichten recently featured an article from the ELZA Institute, highlighting advancements in corneal cross-linking (CXL). This new approach allows the procedure to be conducted at the slit lamp, significantly reducing costs and extending access to advanced eye care in underserved regions. The innovative method is especially effective for treating keratoconus and infectious keratitis. By optimizing UV exposure times, ELZA’s researchers have made CXL more efficient and accessible, democratizing high-quality ophthalmic treatments globally.
Nikki Hafezi, a partner of MESCA Foundation, is leading healthcare transformation in Uzbekistan. MESCA, founded in 2021 by Bakhtiyor Fazylov, focuses on medical education, training, and research. It aims to enhance ophthalmological care, particularly addressing keratoconus, a significant cause of preventable blindness in children. MESCA’s initiatives include training local healthcare professionals and collaborating with institutions like the Andijan State Medical Institute to improve medical practice and education.
Nikki Hafezi, a partner of MESCA Foundation, is leading healthcare transformation in Uzbekistan. MESCA, founded in 2021 by Bakhtiyor Fazylov, focuses on medical education, training, and research. It aims to enhance ophthalmological care, particularly addressing keratoconus, a significant cause of preventable blindness in children. MESCA’s initiatives include training local healthcare professionals and collaborating with institutions like the Andijan State Medical Institute to improve medical practice and education.
